Proteon Therapeutics Inc. (PRTO)’s Financial Results Comparing With Sage Therapeutics Inc. (NASDAQ:SAGE)

Proteon Therapeutics Inc. (NASDAQ:PRTO) and Sage Therapeutics Inc. (NASDAQ:SAGE), both competing one another are Biotechnology companies. We will compare their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Proteon Therapeutics Inc. N/A 0.00 7.21M -1.14 0.00
Sage Therapeutics Inc. 145 -0.86 50.92M -9.74 0.00

Demonstrates Proteon Therapeutics Inc. and Sage Therapeutics Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 shows us Proteon Therapeutics Inc. and Sage Therapeutics Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Proteon Therapeutics Inc. 2,601,010,101.01% 0% -87.5%
Sage Therapeutics Inc. 35,177,892.92% -43.5% -40.6%

Volatility and Risk

Proteon Therapeutics Inc. has a 0.42 beta, while its volatility is 58.00% which is less volatile than S&P 500. Sage Therapeutics Inc. has a 2.51 beta and it is 151.00% more volatile than S&P 500.

Liquidity

The Current Ratio of Proteon Therapeutics Inc. is 5.3 while its Quick Ratio stands at 5.3. The Current Ratio of rival Sage Therapeutics Inc. is 20.1 and its Quick Ratio is has 20.1. Sage Therapeutics Inc. is better equipped to clear short and long-term obligations than Proteon Therapeutics Inc.

Analyst Recommendations

Recommendations and Ratings for Proteon Therapeutics Inc. and Sage Therapeutics Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Proteon Therapeutics Inc. 0 0 0 0.00
Sage Therapeutics Inc. 0 1 5 2.83

Competitively the consensus target price of Sage Therapeutics Inc. is $205, which is potential 37.39% upside.

Institutional & Insider Ownership

The shares of both Proteon Therapeutics Inc. and Sage Therapeutics Inc. are owned by institutional investors at 45.6% and 98.75% respectively. About 0.5% of Proteon Therapeutics Inc.’s share are held by insiders. Comparatively, Sage Therapeutics Inc. has 1.2% of it’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Proteon Therapeutics Inc. -5.35% -11.92% -7.5% -85.69% -83.18% -83.7%
Sage Therapeutics Inc. -8.19% -12.82% -3.85% 20.87% 6.31% 67.39%

For the past year Proteon Therapeutics Inc. had bearish trend while Sage Therapeutics Inc. had bullish trend.

Summary

On 6 of the 11 factors Sage Therapeutics Inc. beats Proteon Therapeutics Inc.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.